The Calcinotto Lab will start in July 2019 as part of the international Institute of Oncology Research IOR affiliated to USI – Università della Svizzera Italiana and part of a large and vibrant immunology community in the sunny part of Switzerland.
The interests of the Lab are focused on a different way of conceiving immunotherapy, blocking factors produced by immune cells that act as nourishment/triggers for tumor growth, progression and as causes of therapy resistance in hormonal-driven tumor such as breast cancer.
- Ph.D. or M.D./Ph.D. (already obtained or soon to be)
- At least one first author publication in a relevant journal
- A highly motivated and ambitious person with a strong interest in research
- Strong background in basic and/or cancer immunology
- Experience with multi-parameter flow cytometry, in vitro assays with primary immune cells and use of mouse models
- Candidates with a background in humanized mouse models are also encouraged to apply
Ph.D. student position
- A highly motivated and enthusiastic person with a strong interest in cancer immunology
- At least one year of previous experience in the lab is highly desirable.
The posts are funded by a 3-year research programme. Salary is highly competitive.
Applicants should submit curriculum vitae, cover letter and contact info for 2 references to email@example.com with reference AC_PostDoc2019 or AC_PhDstudent2019.
More information on Dr. Calcinotto https://www.ncbi.nlm.nih.gov/pubmed/?term=calcinotto+a
• IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
Calcinotto A, et al. Nature. 2018 doi: 10.1038/s41586-018-0266-0.
• Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.
Calcinotto A, et al, Nat Commun. 2018 doi: 10.1038/s41467-018-07305-8.
• Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.
Calcinotto A, et al, Oncoimmunology. 2015
• Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.
Calcinotto A, et al, Cancer Res. 2012 doi: 10.1158/0008-5472.CAN-11-1272.
• Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
Calcinotto A, et al, J Immunol. 2012 doi: 10.4049/jimmunol.1101877. Epub 2012 Feb 8